077 - 8 Databases and How To Use Them with Michelle Lott

Let's Combinate · 22 Mar 2023 · 22m

What this episode covers

Michelle Lott, founder of leanRAQA, walks through eight critical FDA databases for medical device regulatory strategy, including the Product Classification Database, 510(k) Database, and Registration and Listing Database. She explains how to use these tools to determine submission types, identify competitors, and access redacted technical data via FOIA requests. Lott also highlights the importance of the Guidance Document Database and the Code of Federal Regulations (CFR) for understanding specific regulatory requirements and consensus standards.

Most relevant to

early-stage companies

Topics

Mentioned

Companies
leanRAQA
Tools
CDRH Learn, Product Classification Database, 510(k) Database, Registration and Listing Database, Total Product Life Cycle, Guidance Document Database, CFR Title 21

Other shows on the same ground, closest first.

  • Global Medical Device Podcast · 34m

    Understanding and Handling Different Types of Feedback

    Isabella Schmitt, Director of Regulatory Affairs at Proxima Clinical Research, explains the regulatory distinctions between product feedback, complaints, and adverse events for medical device companies. She details the criteria for classifying complaints under 21 CFR 820, the strict timelines for filing Medical Device Reports (MDRs) with the FDA for deaths or serious injuries, and the importance of proactive monitoring via databases like MAUDE. Schmitt emphasizes that all staff must be trained to capture feedback to ensure qualified personnel can determine if an event requires investigation or root cause analysis.

  • Global Medical Device Podcast · 43m

    510(k) Tips and Answers to Frequently Asked Questions for Medical Device Companies

    Mike Drues, president of Vascular Sciences, joins host Jon Speer to explain the 510(k) regulatory pathway for Class II medical devices, emphasizing the requirements for substantial equivalence and device classification. They discuss the three types of 510(k) submissions—Traditional, Special, and Abbreviated—and advise on timing, noting that design freeze and verification/validation testing must be complete before submission, with promissory notes being rarely accepted today. The conversation highlights the importance of clinical evidence based on the totality of evidence rather than pathway type, and details the Refuse to Accept (RTA) administrative review process, urging companies to use RTA checklists to avoid common paperwork errors.

  • Global Medical Device Podcast · 58m

    #404: MedTech 101: What You Need to Know About the Medical Device Industry

    Etienne Nichols hosts Sara Adams and Chris Rush from Greenlight Guru for a foundational overview of the medical device industry. They define medical devices by intended use and labeling, distinguishing roles for Quality, Regulatory, Clinical, and R&D teams. The trio explains FDA classifications (Class I, II, III), regulatory pathways like 510(k) and PMA, and key standards including ISO 13485 and ISO 14971. They emphasize the importance of design controls, risk management, and reading regulations to navigate compliance and market access.

  • Global Medical Device Podcast · 38m

    #342: Planning an FDA Submission

    Ellie Reynolds, Associate Director of Quality Assurance and Regulatory Affairs at Proxima Clinical Research, explains the strategic planning required for FDA medical device submissions. She details the differences between 510(k), De Novo, and PMA pathways, emphasizing the critical role of Q-submissions (pre-submissions) and the eSTAR system in identifying documentation gaps early. Reynolds highlights the importance of realistic timeline management, including the 60-75 day wait for pre-sub meetings and potential review pauses, as well as navigating user fees and building collaborative relationships with FDA review teams.

  • Global Medical Device Podcast · 50m

    #410: Is the MAUDE Database Broken? An Insider’s Take on Adverse Event Reporting Failures

    Regulatory expert Mike Drues joins host Etienne Nichols to critique the FDA’s MAUDE database, arguing that widespread late reporting and poor data hygiene undermine its safety mission. Drues highlights that nearly 30% of reports are late, with major manufacturers like Medtronic, Becton Dickinson, and Dexcom accounting for a disproportionate share of violations. The discussion covers the legal risks of non-compliance, the misuse of MAUDE data for competitive analysis, and recommendations for modernizing the system with AI-driven cross-referencing and tiered reporting urgency.

The summary, chapters and topics are generated from the episode’s audio by this directory, not written by Let's Combinate. The episode itself belongs to its publisher.